Market Overview

Atlas Genetics Expands Executive Team, Appointing Marc Jones as Chief Operating Officer and Chief Financial Officer


Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing
company, today announced the appointment of industry veteran Marc Jones
as Chief Operating Officer ("COO") and Chief Financial Officer ("CFO").

In this dual role, Jones will lead Atlas Genetics' finance and
operations functions, as well as new channel development, and he will
again partner with Jeffrey Luber, President and Chief Executive Officer
of Atlas, in key areas influencing strategic direction and execution.

"We are pleased to welcome Marc to the executive team as Atlas
transitions from clinical proof of concept to its commercial phase
globally," said Luber. "The healthcare landscape is changing rapidly,
with an emerging focus on consumer convenience and rapid testing in
decentralized locations. With the Atlas io® platform's ability to detect
disease through a small, desktop instrument, we are poised to leverage
these growing trends. Having talent of Marc's caliber aboard, joining a
stellar team of executives, will ensure we are ready to lead in new
high-growth mobile/digital and retail health categories. Marc is a
visionary executive with a proven track record of successfully guiding
healthcare companies in new market categories through important
commercial milestones. He has great skill in taking new ideas from
concept to execution on time and on budget."

Jones joins Atlas Genetics from Good Start Genetics, where he served as
the COO and CFO. In that role, Jones and Luber raised successive rounds
of capital and helped lead the turnaround of the company to record
business growth and its ultimate sale to publicly traded Invitae
(NYSE:NVTA).Prior to Good Start Genetics, Jones served as the CFO of T2
Biosystems, where he oversaw the company's successful public offering,
raising nearly $100 million in capital, and helped drive the
commercialization of the company's first FDA approved IVD product.
Previously, Jones held the CFO position at Crashlytics, Ivenix and CHiL
Semiconductor. Earlier in his career, he held a number of corporate
finance positions ranging from Fortune 50 companies to high-growth

About Atlas Genetics

Atlas Genetics is creating a new category of in vitro diagnostics
focused on decentralized, near-patient and point-of-care (POC) testing
for everyone. With routine testing rapidly moving from the "hub" to the
"spokes," Atlas's io® platform is poised to benefit from this growing
trend in decentralized testing. The company's proprietary technology
platform positions Atlas in the vanguard of the rapidly evolving and
increasingly patient-directed landscape of consumer diagnostics, where
convenience, rapid "test and treat," and portability of platform are
becoming critical to success. Atlas aims to meet patients where they are
and improve patient outcomes by arming healthcare professionals with a
simple-to-use, rapid and cost-effective solution for on-demand diagnosis
of infectious diseases. Rapid turnaround times, high accuracy and low
cost are hallmarks of the company's broad platform for a broad range of
infectious diseases. The io® platform offers a sample-to-answer time of
30 minutes, or less, making it possible to carry out infectious disease
tests in primary care clinics and physicians' offices anywhere.

Atlas Genetics' investors include Novartis Venture Fund, Consort
Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson &
Johnson Innovation, RMI Investments and Southwest Ventures Fund.

For further information visit

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at